We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Pathogens Remove Myristic Acid from Immune Cell Signaling Proteins

By LabMedica International staff writers
Posted on 15 Apr 2013
An enzyme produced by the pathogenic bacterium Shigella flexneri selectively removes a fatty acid from certain membrane proteins and modifies their behavior in a fashion that disables the immune system’s communication infrastructure. More...


Myristic acid, a 14-carbon fatty acid, is commonly added to the penultimate, nitrogen-terminus, glycine residue in receptor-associated kinases to confer the membrane localization of the enzyme. The myristic acid has a sufficiently high hydrophobicity to become incorporated into the fatty acyl core of the phospholipid bilayer of the plasma membrane of the eukaryotic cell. In this way, myristic acid acts as a lipid anchor in biomembranes. This modification is conserved across eukaryotic species and occurs on nearly 1% of the cellular proteome. Addition of myristic acid to proteins (myristoylation) has received a lot of attention from researchers due to its crucial role in the transformation of normal cells to cancer cells and for promoting cancer cell growth.

Some pathogenic organisms avoid immune system responses by removing myristic acid from immune cell membrane proteins (demyristoylation) and thereby disrupting communication among the various types of immune cells. Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) described in the April 4, 2013, issue of the journal Nature an irreversible mechanism of protein demyristoylation catalyzed by IpaJ (invasion plasmid antigen J), a previously uncharacterized Shigella flexneri type III effector protein with cysteine protease activity.

They reported that mass spectrometry had showed that IpaJ cleaved the peptide bond between N-myristoylated glycine-2 and asparagine-3 of human ARF1 (ADP-ribosylation factor), thereby providing a new mechanism for host secretory inhibition by a bacterial pathogen. In addition, they showed that IpaJ cleaved an array of N-myristoylated proteins involved in cellular growth, signal transduction, autophagasome maturation, and organelle function.

“Our findings provide insight into severe bacterial infectious diseases, as well as some forms of cancer, in which the attachment of fat molecules to proteins is an essential feature of the disease process,” said senior author Dr. Neal Alto, assistant professor of microbiology at the University of Texas Southwestern Medical Center.

“Normally, a macrophage will engulf an invading bacteria and send out cytokines, proteins that act as cellular alert signals, which in turn recruit more immune cells to the site of infection,” said Dr. Alto. “When the macrophages engulf Shigella, however, the bacteria use IpaJ to cut fatty acids from proteins, which need those fats attached in order to sound the alarm. Doing so buys more time for the bacteria to grow and survive. It is very interesting from a disease process point of view, but it is also important because we now have a potential drug target. The next step will be to identify small molecule inhibitors that are specific to this fat-snipping protease and that might be developed into drugs.”

Related Links:

University of Texas Southwestern Medical Center



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Repetitive Pipette
VWR® Stepper Pro
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: NeoCircle Study Synopsis (George, A.M., Chen, Y., Gladchuk, S. et al. EMBO Molecular Medicine (2026). DOI: 10.1038/s44321-026-00447-z)

Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.